Last update 08 May 2025

MK-4464

Overview

Basic Info

Drug Type
Bispecific killer cell engager (BiKE)
Synonyms
Target
CD16a x CEACAM5 x NKG2D
Action
agonists, antagonists
Mechanism
CD16a agonists(Low affinity immunoglobulin gamma Fc region receptor III-A agonists), CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), NKG2D agonists(NKG2-D type II integral membrane protein agonists)
Therapeutic Areas
Neoplasms
Active Indication
Solid tumor
Inactive Indication-
Originator Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Active Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with MK-4464
NCT05514444
/ Active, not recruitingPhase 1
A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors
100 Clinical Results associated with MK-4464
Login to view more data
100 Translational Medicine associated with MK-4464
Login to view more data
100 Patents (Medical) associated with MK-4464
Login to view more data
100 Deals associated with MK-4464
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 1
Netherlands
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
25 Sep 2022
Solid tumorPhase 1
Israel
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
25 Sep 2022
Solid tumorPhase 1
Canada
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
25 Sep 2022
Solid tumorPhase 1
United States
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
25 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free